1 DEPRESSION PIPELINE REVIEW, H1 2017 The report on Depression Pipeline in Central Nervous System Pharmaceutical category describes the mood disorder means depression in detail. The latest research report published at ReportsnReports Depression Pipeline Report H1 2017 focusses on the key companies involved in therapeutics development. Depression is a mood disorder that causes a persistent feeling of sadness and loss of interest. Signs and symptoms include sleep disturbances, including insomnia or sleeping too much, changes in appetite, anxiety, agitation or restlessness and physical problems, such as back pain or headaches. Treatment includes antidepressants, mood stabilizers or antipsychotics. Pharmaceutical and Healthcare latest pipeline guide Depression - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Depression (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Request for Discount on Report here at https://goo.gl/iWCXgM Companies mentioned in this report are: 4D Pharma PLC, AB Science SA, Acadia Pharmaceuticals Inc, Adamed Sp z oo, Addex Therapeutics Ltd, Aequus Pharmaceuticals Inc, Alkermes Plc, Allergan Plc, Alvogen Korea Co Ltd, Amorsa Therapeutics Inc, Anavex Life Sciences Corp, Angelini Group, Angita BV, Araim Pharmaceuticals Inc, AstraZeneca Plc, Avanir Pharmaceuticals Inc, Axsome Therapeutics Inc, Azevan Pharmaceuticals Inc, BioCrea GmbH, BioLite Inc, Bionomics Ltd, Boehringer Ingelheim GmbH, BristolMyers Squibb Company, Calico LLC, Celgene Corp, Celon Pharma SA, Cerecor Inc, Clera Inc, Delpor Inc, Domain Therapeutics SA, Eisai Co Ltd, Eli Lilly and Company, Evotec AG, F. Hoffmann-La Roche Ltd, Fabre-Kramer Pharmaceuticals Inc, FPRT Bio Inc, GlaxoSmithKline Plc, GliaCure Inc, H. Lundbeck A/S, Heptares Therapeutics Ltd, Hua Medicine (Shanghai) Ltd, Hyundai Pharmaceutical Co Ltd, Impel NeuroPharma Inc, INSYS Therapeutics Inc, Intas Pharmaceuticals Ltd, www.reportsnreports.com
2 DEPRESSION PIPELINE REVIEW, H1 2017 Intra-Cellular Therapies Inc, INVENT Pharmaceuticals Inc, Johnson & Johnson, KemPharm Inc, Lead Discovery Center GmbH, Les Laboratoires Servier SAS, Lixte Biotechnology Holdings Inc, Luye Pharma Group Ltd, Mapi Pharma Ltd, Mapreg SAS, Medlab Clinical Ltd, Meta-IQ ApS, Methylation Sciences Inc, miCure Therapeutics Ltd, Mitsubishi Tanabe Pharma Corp, Navya Biologicals Pvt Ltd, Neuralstem Inc, Neurocrine Biosciences Inc, NeuroNascent Inc, NeurOp Inc, Newron Pharmaceuticals SpA, Nippon Chemiphar Co Ltd, nLife Therapeutics SL, Omeros Corp, Orexigen Therapeutics Inc, Otsuka Holdings Co Ltd, Pfizer Inc, Pherin Pharmaceuticals Inc, Polleo Pharma Ltd, Protagenic Therapeutics Inc, Relmada Therapeutics Inc, Reviva Pharmaceuticals Inc, Richter Gedeon Nyrt, Sage Therapeutics Inc, Saniona AB, SK Biopharmaceuticals Co Ltd, Sound Pharmaceuticals Inc, Sumitomo Dainippon Pharma Co Ltd, Supernus Pharmaceuticals Inc, Suven Life Sciences Ltd, Taisho Pharmaceutical Holdings Co Ltd, Takeda Pharmaceutical Company Ltd, Tetra Discovery Partners LLC, Trevena Inc, TRImaran Pharma Inc, VistaGen Therapeutics Inc, Zhejiang Huahai Pharmaceutical Co Ltd, Zogenix Inc, Zysis Ltd. Inquire for this report at https://goo.gl/WDt5aR Depression (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. In depth, this report provides the following - The pipeline guide provides a snapshot of the global therapeutic landscape of Depression (Central Nervous System).
www.reportsnreports.com
3 DEPRESSION PIPELINE REVIEW, H1 2017 - The pipeline guide reviews pipeline therapeutics for Depression (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources. - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages. - The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities. - The pipeline guide reviews key companies involved in Depression (Central Nervous System) therapeutics and enlists all their major and minor projects. - The pipeline guide evaluates Depression (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type. - The pipeline guide encapsulates all the dormant and discontinued pipeline projects. - The pipeline guide reviews latest news related to pipeline therapeutics for Depression (Central Nervous System) Purchase this Report at https://goo.gl/SJq6Ys About Us: ReportsnReports.com is your single source for all market research needs. Our database includes 500,000+ market research reports from over 95 leading global publishers & in-depth market research studies of over 5000 micro markets. Order report by calling ReportsnReports.com at +1 888 391 5441 OR send an email on sales@reportsandreports.com with your contact details.
www.reportsnreports.com